Therapeutic potential of *Commiphora molmol* extract loaded on chitosan nanofibers against experimental cryptosporidiosis

Azza M Fahmy\(^1\), Zeinab H Fahmy\(^1\), Eman A Aly\(^1\), Amal M Elshenawy\(^1\), Eman A El-Wakil\(^2\)

Parasitology Laboratory, Department of Immunology and Drug Evaluation\(^1\) and Medicinal Chemistry Laboratory\(^2\), Theodor Bilharz Research Institute, Imbaba, Giza, Egypt

ABSTRACT

**Background:** Cryptosporidium is a life-threatening intestinal pathogen in immunocompromised patients. Currently, there is no entirely successful drug against cryptosporidiosis. Several reports utilizing nanotechnology combined with herbal medicine were published to evaluate its efficacy in treatment of intestinal pathogens.

**Objectives:** To evaluate the anti-cryptosporidial efficacy of *Commiphora molmol* extract and its conjugation with chitosan nanofibers (CsNFs) for treatment of cryptosporidiosis in mice.

**Material and Methods:** Sixty-five male albino mice were infected orally with \(10^4\) *Cryptosporidium* oocysts. They were grouped and treated with nanazoxid (NTZ) (100 mg/kg), *C. molmol* extract (500 mg/kg), and *C. molmol* loaded chitosan nanofibers (Cm-CsNFs) at 25, 50, and 100 mg/kg. The scarification of mice was done after 5 and 10 days of treatments. Assessment of the treatments’ efficacy was achieved using parasitological parameters: oocysts and trophozoites counts, and histopathological examination.

**Results:** *C. molmol* extract and Cm-CsNFs (100 mg/kg) significantly reduced the mean number of intestinal oocysts. All the treatment regimens significantly \((P<0.05)\) diminished the mean number of trophozoites relative to the infected non-treated group. Apparent pathological alterations in intestinal tissues were consistent with cryptosporidiosis. Cryptosporidium-induced pathological alterations were improved remarkably in Cm-CsNFs (100 mg/kg) group.

**Conclusion:** Our study highlights the efficacy of *C. molmol* as an extract or conjugated with CsNFs in declining cryptosporidiosis and attenuating *Cryptosporidium*-induced intestinal injury.

**Keywords:** Chitosan nanofibers, *C. molmol*, Cryptosporidium, histopathological alterations, myrrh.

**Received:** 28 December, 2020, **Accepted:** 10 February, 2021.

**Corresponding Author:** Azza M Fahmy, **Tel.**: +20 1004335729, **E-mail:** azzafhmy@gmail.com

**Print ISSN:** 1687-7942, **Online ISSN:** 2090-2646, Vol. 14, No. 1, April, 2021.

INTRODUCTION

Cryptosporidiosis is a principal cause of diarrhea in both humans and animals all over the world, and is caused by several species of the intestinal protozoan parasite *Cryptosporidium*. The infection is potentially life-threatening and a significant contributor to early childhood mortality. It is one of the most widespread waterborne protozoan (WBP) in developing countries. Egypt has contributed to almost 1/3 (36/120) of WBP reports in Africa. Cryptosporidium is a monoxenous Apicomplexan parasite, completing its entire life cycle within a single host. The infectious form of the parasite, known as the oocyst, is resistant to many standard disinfectants, due to its hard wall. The small size, low infectious dosage, long-term viability, and multiple exposure routes make Cryptosporidium a very difficult pathogen to monitor. Cryptosporidium oocyst comprises four sporozoites which are released when oocysts are swallowed by the host to invade the apical intestinal epithelial cells. Then, it undergoes asexual and sexual replication processes, leading to the development of new oocysts that are expelled by the infected host.

Presently, the available medications are not entirely successful against cryptosporidiosis. Nitazoxanide is the only FDA-approved drug used for the treatment in immunocompetent persons, although it is not entirely effective. Besides NTZ, a few other commercial medications are not FDA-approved for the treatment. Thus there is a crucial need for the production of new safe and efficient therapeutic agents.

Plant extracts have advantages over prescription drugs; not only are they more cost-effective, easier to produce and process, more available, and more effective, but they also tend to have fewer adverse effects. Conjugation of plant extracts into nanostructured drug delivery systems, enhanced their therapeutic properties, potency, and safety of the active entity. *C. molmol*, known in folklore medicine as Myrrh, is one of the effective plants...
commonly used as an anti-parasitic. Myrrh is believed to be more effective in the prevention of infectious diseases, relying on Egyptian beliefs and culture\textsuperscript{[14,15]}. Several studies have explored and established the effectiveness of \textit{C. molmol} against various diseases such as anti-bacterial\textsuperscript{[16]}, anti-inflammatory, analgesic, anti-hyperlipidemic\textsuperscript{[17]}, and anti-cancer agent\textsuperscript{[18]} as well. Also, it has a strong and unique antibiotic activity\textsuperscript{[19]}. It has been used in the treatment of hypertension\textsuperscript{[20]}, respiratory infections\textsuperscript{[21]}, healing wound injuries, and ulcers\textsuperscript{[22]}. \textit{C. molmol} effectively treated protozoa\textsuperscript{[23,24]} and helminths\textsuperscript{[25-27]} infections. An increasing number of studies proved the safety of \textit{C. molmol} in experimental studies at a dosage of 500 mg/kg/day\textsuperscript{[28-30]}.

Because of their unique properties, electrospun nanofibers are regarded as a promising drug delivery system for plant extracts, and electrospinning is a successful way to manufacture them\textsuperscript{[31]}. The chitosan nanofiber is a remarkable material in the controlled drug delivery process. It decreases the side effects of the pharmaceutical ingredient and preserves the dosage of the drug concentration within the effective therapeutic range allowing it high potential for use in many fields\textsuperscript{[32]}. Combining nanofibers with plants is a way to integrate the physical properties of the nanofibers’ structure and the chemical and antiparasitic properties of the plants\textsuperscript{[33]}.

Based on the proven advantages of the incorporation of chitosan nanofibers into the modern drug delivery system, the present study aimed to investigate the efficacy of \textit{C. molmol} loaded chitosan nanofibers (Cm-CsNFs) as a curing agent of cryptosporidiosis in experimental mice.

**MATERIAL AND METHODS**

This case control study was conducted at Theodor Bilharz Research Institute (TBRJ), Giza, Egypt, during the period from September to November 2019.

**Experimental animals:** The research was performed on 65 male Swiss albino mice aged 4-5 weeks and weighing 20-24 gm in Theodor Bilharz Research Institute (TBRJ) in Giza, Egypt. Mice were free from any parasitic infection as determined by microscopic examination of their stools for three successive days. Animals were kept in separate laboratory cages under optimum conditions. Private laboratory mouse pellets as food and water ad libitum were also readily accessible.

**Cryptosporidium oocysts:** Cryptosporidium oocysts were obtained from the Animal Reproduction Research Institute (ARRI) Giza, Egypt. The fecal samples were collected from naturally infected diarrheic calves (1-2 months old), and concentrated using the formol-ether concentration technique\textsuperscript{[33]}. The inoculum was adjusted to infect mice orally with $10^4$ Cryptosporidium oocysts using esophageal tube according to Benamrouz \textit{et al.}\textsuperscript{[34]}. Fecal pellets were obtained from inoculated mice individually after infection and exposed to parasitological examination using the modified Ziehl-Neelsen stain\textsuperscript{[35]} to detect Cryptosporidium spp. oocysts and to ensure that the mice were successfully infected.

**Treatment:** Nanazoxid (Medizen pharmaceutical industries for Utopia pharmaceuticals) was given via the oral route as a suspension (100 mg/kg/d) for ten consecutive days\textsuperscript{[36]}.

**Preparation of \textit{C. molmol} extract:** Two hundred grams of fine powder of \textit{C. molmol} was obtained from the local market, Cairo, Egypt, and the herbal extract preparation according to Shalaby and hammouda\textsuperscript{[17]} was then orally administered daily to male mice at doses of 500 mg/kg body weight.

**Preparation of chitosan nanofibers:** The electrospinning technique following the method of Mengistu Lemma and his colleagues\textsuperscript{[37]} was used to fabricate chitosan nanofibers.

**\textit{C. molmol} loading on chitosan nanofibers:** Preparation of \textit{C. molmol} loaded CsNFs was conducted at three concentrations of \textit{C. molmol} (25, 50, and 100 mg/kg) as per Ibrahim \textit{et al.}\textsuperscript{[38]}.

**Experimental design:** Mice were classified into 6 groups (I-VI), and each was divided equally into two subgroups (A and B), according to the time of scarification (5 and 10 days after treatment, respectively). Treatment began on the first day of oocyst shedding and continued for 10 consecutive days for all groups. All subgroups consisted of 5 mice in each, in addition to 5 mice that served as the normal non-infected control for histopathological study. The following table shows the studied groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Mice infected and not treated.</td>
</tr>
<tr>
<td>II</td>
<td>Infected mice and treated with NTZ (100 mg/kg)</td>
</tr>
<tr>
<td>III</td>
<td>Infected mice and treated with \textit{C. molmol} extract (500 mg/kg)</td>
</tr>
<tr>
<td>IV</td>
<td>Infected mice and treated with \textit{C. molmol} loaded chitosan nanofibers (Cm-CsNFs) at a dose of 25 mg/kg body weight (BW)</td>
</tr>
<tr>
<td>V</td>
<td>Infected mice and treated with (Cm-CsNFs) at a dose of 50 mg/kg BW</td>
</tr>
<tr>
<td>VI</td>
<td>Infected mice and treated with (Cm-CsNFs) at a dose of 100 mg/kg BW</td>
</tr>
</tbody>
</table>
Parasitological studies: After treatment, fresh fecal pellets from each mouse in the study groups were collected and labeled individually for oocyst count. Duodenal content was also obtained for trophozoite enumeration after scarification of mice. Cryptosporidium oocyst and vegetative forms were stained by modified Ziehl-Neelsen stain and examined microscopically. The number of oocysts was counted in ten high-powered fields; the arithmetic means of oocysts for each animal and then for each group of animals were determined, and the same was calculated for the trophozoites. The percentage reduction in parasite count was calculated as: [(mean number of parasites in the control group - mean number of parasites in the treated group) / (mean number of parasites in the treated group)]* 100.

Histopathological examination: A two cm portion of duodenum was dissected from each mouse, fixed in 10% neutral formalin then embedded in paraffin. To determine the structural alterations in the affected tissues, the obtained sections were stained with hematoxylin and Eosin (H&E) as per Cardiff et al.[39].

Statistical analysis: The software package used to analyze the data statistically was GraphPad Prism version 7.00 (GraphPad Software, La Jolla California USA). Data were expressed as means ± standard error. Comparisons between the controls and experimental groups were carried out using Student’s t-test according to Snedecor and Cochran[40]. The difference between the experimental groups was considered significant at P < 0.05.

Ethics statement: All animals handled in the current laboratory research were used in compliance with the ethical and technical regulations of the TBRI, Giza, Egypt, on animal rights for scientific purposes. Dealing with the experimental animals was conducted according to the Internationally Valid Guidelines and the institution responsible for animal ethics.

RESULTS

Parasitological study: It was observed that NTZ significantly reduced oocyst shedding in the stool to $3.23 \times 10^3$ and $1.84 \times 10^3$, which represented about 44% and 79% reduction of oocysts, 5 days (Table 1) and 10 days after treatment (Table 2), respectively relative to infected untreated controls. This observation was significantly maintained for C. molmol extract (500 mg/kg) and Cm-CsNFs (100 mg/kg) with reduced mean number of intestinal oocysts to $3.4 \times 10^3$ and $2.84 \times 10^3$, reaching about 41% and 51% respectively. Inhibition of infection relative to untreated infectious control was significant ($P<0.05$) 5 days after treatment (Table 1). Reduction increased after 10 days (Table 2) where C. molmol extract (500 mg/kg), Cm-CsNFs (50 mg/kg), and Cm-CsNFs (100 mg/kg) produced a significant decrease ($P<0.05$) in the mean counts amounting to $2.67 \times 10^3, 3.76 \times 10^3$ and $1.72 \times 10^3$, with a reduction of ~ 70%, 58%, and 81%, respectively, relative to the infected non treated group. No evidence of improvement was recorded due to treatment with Cm-CsNFs at the dosage of 25 mg/kg ($P>0.05$), as the percent reduction was approximately 16% (Table 2).

The effect of treatments against Cryptosporidium vegetative forms in the intestine was depicted in tables (3 and 4). All the treatment schedules significantly ($P<0.05$) diminished the mean number of trophozoites compared with the infected non treated group. The most obvious decline was recorded in Cm-CSNFs (100 mg/kg) representing the percent reduction of about 80% and 68% after 5 days (Table 3) and 10 (Table 4) days of treatment, respectively. While the minimum decrease in the mean number of trophozoites was observed in the infected group treated with Cm-CsNFs (25 mg/kg) and the percent of reductions were 43% and 27% after 5 and 10 days of treatment, respectively.

Histopathological study: Compared to the uninfected normal group (Fig. 1a), the H & E-stained intestinal sections of the Cryptosporidium-infected control group (Fig. 1b) showed, apparent pathological alterations consistent with cryptosporidiosis. NTZ was able to diminish tissue damages without complete recovery (Fig. 1c). Treatment of the infected group with C. molmol extract (500 mg/kg) produced no marked improvement in the villus architecture (Fig. 1d). Intestinal sections of the infected treated group with Cm-CsNFs at 25 mg/kg (Fig. 1e) and Cm-CsNFs (50 mg/kg) (Fig. 1f) showed slight to moderate pathological changes in the intestinal sections. Compared to the infected untreated group, the histopathological injuries in intestinal

### Table 1. The mean number and percentage reduction of Cryptosporidium oocyst shedding in mice after 5 days of receiving different treatment regimens.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SEM X 10³</th>
<th>% reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected, non-treated (Control)</td>
<td>5.80 ± 0.23</td>
<td>44.19</td>
<td>a</td>
</tr>
<tr>
<td>NTZ (100 mg/kg)</td>
<td>3.23 ± 0.49</td>
<td>64.51</td>
<td>a, ns</td>
</tr>
<tr>
<td>C. molmol extract (500 mg/kg)</td>
<td>3.40 ± 0.19</td>
<td>41.29</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (25 mg/kg)</td>
<td>5.45 ± 0.20</td>
<td>58.69</td>
<td>ns, b</td>
</tr>
<tr>
<td>Cm-CsNFs (50 mg/kg)</td>
<td>5.31 ± 0.24</td>
<td>44.19</td>
<td>ns, b</td>
</tr>
<tr>
<td>Cm-CsNFs (100 mg/kg)</td>
<td>2.84 ± 0.19</td>
<td>50.96</td>
<td>a, ns</td>
</tr>
</tbody>
</table>

SEM: standard error; NTZ: Nanazoxid; Cm-CsNFs: C. molmol loaded on chitosan nanofibers. Significant if $P<0.05$: a: Significant difference in comparison to the infected control group; b: Significant difference in comparison to NTZ treated group; ns: Non-significant.
tissue sections were reduced and the improvement of villi structure was remarkably noticed. Most of the villi were intact with their tall columnar epithelium and mild inflammatory cells, along with improved degenerative changes in the glands (Fig. 1g) in the group of infected mice and treated with Cm-CsNFs at 100 mg/kg.

Table 2. The mean number and the percentage reduction of Cryptosporidium oocyst shedding in mice after 10 days of receiving different treatment regimens.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SEM X 10³</th>
<th>% reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected, non-treated (Control)</td>
<td>8.96 ± 0.45</td>
<td>79.43</td>
<td>a</td>
</tr>
<tr>
<td>NTZ (100 mg/kg)</td>
<td>1.84 ± 0.59</td>
<td>70.15</td>
<td>a, ns</td>
</tr>
<tr>
<td>C. molmol extract (500 mg/kg)</td>
<td>2.67 ± 0.23</td>
<td>67.93</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (25 mg/kg)</td>
<td>7.50 ± 0.36</td>
<td>58.05</td>
<td>a, b</td>
</tr>
<tr>
<td>Cm-CsNFs (50 mg/kg)</td>
<td>3.76 ± 0.31</td>
<td>58.70</td>
<td>a, b</td>
</tr>
<tr>
<td>Cm-CsNFs (100 mg/kg)</td>
<td>1.72 ± 0.10</td>
<td>80.75</td>
<td>a, ns</td>
</tr>
</tbody>
</table>

SEM: standard error; NTZ: Nanazoxid; Cm-CsNFs: C. molmol loaded on chitosan nanofibers. Significant if P<0.05. a: Significant difference in comparison to the infected control group; b: Significant difference in comparison to NTZ treated group; ns: Non-significant.

Table 3. The mean number and the percentage reduction of Cryptosporidium trophozoites in intestinal contents in mice after 5 days of receiving different treatment regimens.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SEM X 10³</th>
<th>% reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected, non-treated (Control)</td>
<td>17.60 ± 0.81</td>
<td>56.82</td>
<td>a</td>
</tr>
<tr>
<td>NTZ (100 mg/kg)</td>
<td>6.80 ± 0.63</td>
<td>61.36</td>
<td>a</td>
</tr>
<tr>
<td>C. molmol extract (500 mg/kg)</td>
<td>7.00 ± 0.70</td>
<td>60.23</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (25 mg/kg)</td>
<td>10.00 ± 0.72</td>
<td>43.18</td>
<td>a, b</td>
</tr>
<tr>
<td>Cm-CsNFs (50 mg/kg)</td>
<td>7.60 ± 0.65</td>
<td>56.82</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (100 mg/kg)</td>
<td>3.60 ± 0.51</td>
<td>79.55</td>
<td>a, ns</td>
</tr>
</tbody>
</table>

SEM: standard error; NTZ: Nanazoxid; Cm-CsNFs: C. molmol loaded on chitosan nanofibers. Significant if P<0.05. a: Significant difference in comparison to the infected control group; b: Significant difference in comparison to NTZ treated group; ns: Non-significant.

Table 4. The mean number and the percentage reduction of Cryptosporidium trophozoites in intestinal contents in mice after 10 days of receiving different treatment regimens.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SEM X 10³</th>
<th>% reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected, non-treated (Control)</td>
<td>36.80 ± 1.98</td>
<td>58.70</td>
<td>a</td>
</tr>
<tr>
<td>NTZ (100 mg/kg)</td>
<td>15.20 ± 2.04</td>
<td>51.63</td>
<td>a, ns</td>
</tr>
<tr>
<td>C. molmol extract (500 mg/kg)</td>
<td>17.80 ± 2.08</td>
<td>56.17</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (25 mg/kg)</td>
<td>26.80 ± 0.86</td>
<td>27.17</td>
<td>a, b</td>
</tr>
<tr>
<td>Cm-CsNFs (50 mg/kg)</td>
<td>19.80 ± 0.86</td>
<td>47.28</td>
<td>a, ns</td>
</tr>
<tr>
<td>Cm-CsNFs (100 mg/kg)</td>
<td>11.80 ± 0.37</td>
<td>67.93</td>
<td>a, ns</td>
</tr>
</tbody>
</table>

SEM: standard error; NTZ: Nanazoxid; Cm-CsNFs: C. molmol loaded on chitosan nanofibers. Significant if P<0.05. a: Significant difference in comparison to the infected control group; b: Significant difference in comparison to NTZ treated group; ns: Non-significant.

Fig. 1. Intestinal sections of mice stained with H & E (a–g). (a) Photomicrograph of intestinal tissue of uninfected group showing intact villi (V), lamina propria (LP), and goblet cell (G), (X40); (b) Infected mice displayed shortening, fusion and blunting of the villi with irregular brush border and reduction of goblet cells, (X40); (c) Infected mice and treated with NTZ showing improvement in the villi structure (V), and near normal columnar epithelium (arrow), (X200); (d) Infected mice treated with C. molmol showing disturbed villous architecture (V), and reduction in goblet cells (G), (X 100); (e) Infected mice treated with Cm-CsNFs at 25 mg/kg showing moderate pathological alterations, where many glands (G) display degenerative changes and moderate inflammatory cells (I), (X 200); (f) Infected mice treated with Cm-CsNFs at 50 mg/kg showing mild inflammatory cells (I), where intact glands (G) with many villi (V) could be detected, (X 200); (g) Infected mice treated with Cm-CsNFs at 100 mg/kg showing remarkable improvement, where most of the villi are intact (arrow) with their tall columnar epithelium, mild inflammatory (I) cells in the core of the villi (V), together with mild degenerative changes in the glands (G), (X 400).
Nanofibers in treatment of cryptosporidiosis

Fahmy et al.,

DISCUSSION

The findings of the current investigation revealed that NTZ was successful in reducing oocyst shedding, intestinal trophozoites and tissue damage, but did not completely dispose of Cryptosporidium infection throughout the trial periods. Over the range of concentration dosages, Cm-CsNFs triggered significant destruction of oocysts at 100 μg/ml 5 days post-treatment, while 50 μg/ml was the minimal concentration dose that had a significant destructive rate on the oocysts 10 days after treatment in experimental mice. Regarding the impact of the treatments on the intestinal vegetative forms, interestingly, all the treatments significantly diminished the mean counts all through the experimental periods.

The noted observation emerging from the compared data was that Cm-CsNFs (100 mg/kg) is more effective against oocyst and trophozoite of Cryptosporidium than NTZ, which is the mainline, standard treatment for infection in adults and children[46]. Also, the chitosan loaded C. molmol gave better result than the sole extract C. molmol despite the high dose used (500 mg/kg). This is because plant extracts loaded in nanostructured drug delivery systems have the advantages to improve their therapeutic effectiveness and extension of their antiparasitic activity[43] because of their smaller particle size, larger surface area, and faster dissolution rate[42].

Existence of the tannins phenolic compound as one of the components of Commiphora spp.[43,44], is accountable for its antiprotozoal activity[45,46]. Tannins bind proteins to mucous surfaces rendering them less permeable with poor absorption due to the protective coating of coagulated protein, making the expulsion of parasites easier[45]. The conjugation of C. molmol into the GSNFs permitted the adsorption of C. molmol to the surface of the wall of the oocysts[47,48], contributing to a shift in its integrity and permeability leading to their damage[49]. However, the additive effects of C. molmol and CsNFs conjugation observed in the present study may be due to the different synergistic mechanisms of action of both substances.

Dislodging of brush border and asymmetrical loss of epithelial cells with shortening and fusion of villi reflects the pathological alterations in response to cryptosporidiosis infection[50,51]. These progressions are brought about by trophozoite of the Cryptosporidium and the significant infiltration of lymphocytes[52,53]. The improvement in the pathological picture was indicated by the recuperation of the brush border to regular structure in response to treatment with NTZ and Cm-CsNFs (100 mg/kg). This can be attributed to the decreased number of oocysts (Tables 1 and 2) and trophozoites (Tables 3 and 4), and/or reduction of cytokines and inflammatory cells production[51,54].

Reduced immune cell production is attributed to the impact of the flavonoids which are one of the chemical ingredients of C. molmol[55,56] with their known anti-inflammatory activities[55,56]. All in all, this study demonstrated the restoration of the normal structures of villi and the reduction of oocysts shedding in the stool and duodenal content of experimental animals in response to treatment with CsNFs loading C. molmol (100 mg/kg). Moreover, the superiority of the effect of nano form structure of C. molmol over NTZ, the drug of choice against cryptosporidiosis was observed.

In conclusion, our study highlights the role of C. molmol (at dosages of 500 mg/kg and its conjugation with CsNFs in various dose regimens) in declining Cryptosporidium infestation and attenuating Cryptosporidium-induced intestinal damage. Further investigations should be applied before approving C. molmol either alone or loaded in a nanostructured drug delivery system for the battle against this disease of zoonotic importance. Our findings may likewise form the basis for further study of related infections in animals and man.

Acknowledgments: We appreciate Dr. Sahar Darwishi, head of the Pathology Department, National Organization for Drug Control and Research, Egypt for her technical assistance of pathological methodology and valuable comments.

Authors' contributions: Fahmy AM designed the study, analyzed statistical data, drafted, and reviewed the manuscript. Fahmy ZH, Aly EA, and Elshenawy AM contributed to the study design, conducted the laboratory investigations, and drafted the manuscript. El-Wakil EA performed the plant extraction. All authors approved the final version.

Conflict of interest: The authors declare that there is no conflict of interest.

Financial statement: No financial support was provided.

REFERENCES

5. Ahmed SA, Guerrero Flórez M, Kananis P. The impact of water crises and climate changes on the transmission
Nanofibers in treatment of cryptosporidiosis

Fahmy et al.,

in the domestic rabbit

Commiphora molmol

Punica

Myrrh mediates haem oxygenase-1 expression

J Egypt Soc Parasitol, and

infection in

45.

44.

43.

42.

41.

40.

39.

38.

37.

36.

35.


